Major Organs and Cancer —
Training activity: 4

Details

Interpret and report the results of a CSF xanthochromia scan

Type

Entrustable training activity (ETA)

Evidence requirements

Evidence the activity has been undertaken by the trainee repeatedly, consistently, and effectively over time, in a range of situations. This may include occasions where the trainee has not successfully achieved the outcome of the activity themselves. For example, because it was not appropriate to undertake the task in the circumstances or the trainees recognised their own limitations and sought help or advice to ensure the activity reached an appropriate conclusion. ​

Reflection at multiple timepoints on the trainee learning journey for this activity.

Reflective practice guidance

The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.

Before action

What does success look like?

• Identify what is expected of you in relation to accurately interpreting the spectrophotometric scan results for CSF xanthochromia and reporting them in line with specific criteria.
• Consider how the learning outcomes apply, specifically in relation to accurately interpreting the scan results and ensuring the report reflects adherence to national guidelines.
• Discuss with your training officer to gain clarity of what is expected of you in relation to the specific spectrophotometric criteria for interpreting xanthochromia and the necessary elements of the clinical report.

What is your prior experience of this activity?

• Think about what you already know about CSF analysis or the general principles of spectrophotometry.
• Consider possible challenges you might face during the activity, such as interpreting complex or atypical scan results, applying specific time-dependent interpretive criteria, or understanding the clinical context of suspected subarachnoid haemorrhage.
• Recognise the scope of your own practice for this activity i.e. know when you will need to seek advice or help, and from whom. You will need to seek advice from your Training Officer when required, for example if an atypical scan result requires verification or if the application of specific time criteria conflicts with available clinical data.
• Acknowledge how you feel about undertaking this time-critical and specialised analysis and interpretation.

What do you anticipate you will learn from the experience?

• Consider the specific skills you want to develop, such as mastering the application of interpretive criteria for CSF xanthochromia.
• Identify the specific insights you hope to gain into the clinical significance of xanthochromia in diagnosing subarachnoid haemorrhage and the analytical principles of spectrophotometry.

What additional considerations do you need to make?

• Consult actions identified following previous experiences with CSF analysis or spectrophotometry.
• Identify important information you need to consider before embarking on the activity, such as the laboratory’s specific SOP for performing the scan, reviewing relevant guidelines for subarachnoid haemorrhage investigation, and understanding potential analytical interferences.

In action

Is anything unexpected occurring?

• Are you noticing anything surprising or different from what you anticipate whilst examining the spectrophotometric scan or reviewing the results of the CSF xanthochromia test?
• Are you encountering situations such as:
  • Borderline spectral results or evidence of interfering substances that complicate the definitive interpretation of xanthochromia?
  • The time elapsed since the suspected subarachnoid haemorrhage (SAH) appears inconsistent with the observed spectral peaks?
  • Technical issues arise with the spectrophotometer calibration or scan quality that affect result validity?

How are you reacting to the unexpected development?

• How is this impacting your actions? For example, are you responding to the situation appropriately? Are you adapting or changing your approach to verifying the sample quality or applying time-dependent criteria?
• Consider the steps you are taking in the moment, such as:
  • Immediately consulting the SOP or clinical guidelines to rigorously apply the time-dependent interpretation criteria
  • Seeking a second opinion from the duty biochemist to verify the spectral interpretation of an equivocal result
• How are you feeling in that moment? For instance, are you finding it difficult to definitively classify the scan results (positive/negative)? Is it affecting your confidence in reporting this time-critical test accurately?

What is the conclusion or outcome?

• Identify how you are working within your scope of practice. For example, are you successfully applying the spectrophotometric criteria to classify xanthochromia according to guidelines? Or are you needing support because the complexity of the atypical scan results requires senior pathological interpretation before reporting?
• What are you learning as a result of the unexpected development? For example, are you mastering the application of time-dependent interpretation criteria for CSF xanthochromia? Or gaining insight into the analytical limitations and interferences of spectrophotometry in CSF?

On action

What happened?

• Begin by summarising the key steps you took when interpreting the CSF xanthochromia scan results and drafting the report.
• Consider specific events, actions, or interactions which felt important, such as how you applied the spectrophotometric criteria to the scan data or the steps taken to verify the timing of the sample collection relative to the suspected subarachnoid haemorrhage (SAH).
• Include any ‘reflect-in-action’ moments where you had to adapt to the situation as it unfolded, for instance, immediately seeking a second opinion on the interpretation of a borderline or equivocal scan result.
• How did you feel during this experience, e.g., did you feel confident in applying the specific time-dependent criteria or hesitant when assessing the scan quality?

How has this experience contributed to your developing practice?

• Identify what learning you can take from this experience regarding time-critical and specialised analysis interpretation. What strengths did you demonstrate, e.g., meticulous adherence to guidelines for interpretation?
• What skills and/or knowledge gaps were evident, e.g., unfamiliarity with the common analytical interferences in spectrophotometric CSF analysis?
• Compare this experience against previous engagement with similar activities – were any previously identified actions for development achieved? Has your practice improved in integrating time-dependent clinical information into analytical interpretation?
• Identify any challenges you experienced, such as needing to seek advice or clarification on scope of practice regarding reporting a result that conflicted with the expected clinical presentation (e.g., clear xanthochromia but recent trauma), and how you reacted to this.

What will you take from the experience moving forward?

• Identify the actions or ‘next steps’ you will now take to support the assimilation of what you have learnt, including from any feedback you have received, with regards to improving the accuracy and speed of CSF xanthochromia interpretation.
• What will you do differently next time you approach interpreting a CSF xanthochromia scan, for instance, by proactively reviewing the patient’s full clinical history and sample collection timing prior to viewing the scan?
• Do you need to practise any aspect of the activity further, such as applying specific interpretive criteria to atypical scan results or key learning outcomes related to adhering to national guidelines?

Beyond action

Have you revisited the experiences?

• How have your subsequent experiences of interpreting other specialised analyses or encountering further CSF samples since completing this specific training activity led you to revisit your initial approach or decisions during that activity? For example, how a subsequent analysis of a complex fluid (e.g., pleural fluid) forced you to re-evaluate the meticulousness of your sample integrity checks and pre-analytical assessment applied during your first attempt at interpreting a time-critical CSF xanthochromia scan.
• Considering what you understand about spectrophotometric analysis, the time-dependent nature of xanthochromia, and the clinical context of subarachnoid haemorrhage now, were the actions or considerations you identified after your initial reflection on this training activity sufficient? How have you since implemented or adapted improvements in your specialised test interpretation methodology and adherence to procedural criteria based on further learning and experiences? For example, how you proactively reviewed and integrated academic knowledge on CSF formation and pathology to verify the validity of spectral findings when reporting.
• Has discussing specific CSF xanthochromia cases or the impact of pre-analytical variables on specialised tests with colleagues, peers, or supervisors changed how you now view your initial experience in this training activity? For example, how professional storytelling with a senior colleague about a time when a false positive result occurred due to poor sample centrifugation refined your understanding of the critical nature of meticulous laboratory steps for specialised assays.

How have these experiences impacted upon current practice?

• How has the learning from this initial training activity, in combination with subsequent specialised test interpretation experiences, contributed to your overall confidence and competence in interpreting spectral data and time-critical specialised tests, particularly in preparing for assessments like Case-Based Discussions (CBDs)? For example, how your accumulated ability in recognising the importance of sample integrity and applying specific time-dependent analytical criteria now enables you to confidently discuss the validity and limitations of specialised fluid analysis during a CBD assessment.
• How has reflecting back on this specific training activity, combined with everything you’ve learned since, shaped your current approach to interpreting specialised analyses? How does this evolved understanding help you identify when something is beyond your scope of practice or requires escalation? For example, how your evolved approach means you now routinely seek advice from the duty biochemist immediately when interpreting atypical scan results or when adherence to time limits for subarachnoid haemorrhage diagnosis is unclear, recognising this highly time-critical test requires senior pathological verification.
• Looking holistically at your training journey, how has this initial CSF xanthochromia experience, revisited with your current perspective, contributed to your development in meeting the learning outcomes related to analysing and interpreting biochemical data? For example, how this foundational experience has supported your development in approaching specialised, time-critical tests and understanding the profound impact of sample integrity on diagnostic utility.

Relevant learning outcomes

#	Outcome
# 1	Outcome Perform biochemical assays involved in the assessment of major organ function and cancer diagnosis and monitoring.
# 2	Outcome Analyse and interpret biochemical data generated in the assessment of major organ function and cancer diagnosis and monitoring.
# 3	Outcome Evaluate the national guidelines for diagnosis and management of diseases associated with the major organ systems and cancer.